Stark Mitchell S, Klein Kerenaftali, Weide Benjamin, Haydu Lauren E, Pflugfelder Annette, Tang Yue Hang, Palmer Jane M, Whiteman David C, Scolyer Richard A, Mann Graham J, Thompson John F, Long Georgina V, Barbour Andrew P, Soyer H Peter, Garbe Claus, Herington Adrian, Pollock Pamela M, Hayward Nicholas K
Oncogenomics Group, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4029, Australia ; School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD 4059, Australia.
Statistics Unit, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4029, Australia ; Clinical Trials and Biostatistics Unit, QIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4029, Australia.
EBioMedicine. 2015 May 12;2(7):671-80. doi: 10.1016/j.ebiom.2015.05.011. eCollection 2015 Jul.
The overall 5-year survival for melanoma is 91%. However, if distant metastasis occurs (stage IV), cure rates are < 15%. Hence, melanoma detection in earlier stages (stages I-III) maximises the chances of patient survival. We measured the expression of a panel of 17 microRNAs (miRNAs) (MELmiR-17) in melanoma tissues (stage III; n = 76 and IV; n = 10) and serum samples (collected from controls with no melanoma, n = 130; and patients with melanoma (stages I/II, n = 86; III, n = 50; and IV, n = 119)) obtained from biobanks in Australia and Germany. In melanoma tissues, members of the 'MELmiR-17' panel were found to be predictors of stage, recurrence, and survival. Additionally, in a minimally-invasive blood test, a seven-miRNA panel (MELmiR-7) detected the presence of melanoma (relative to controls) with high sensitivity (93%) and specificity (≥ 82%) when ≥ 4 miRNAs were expressed. Moreover, the 'MELmiR-7' panel characterised overall survival of melanoma patients better than both serum LDH and S100B (delta log likelihood = 11, p < 0.001). This panel was found to be superior to currently used serological markers for melanoma progression, recurrence, and survival; and would be ideally suited to monitor tumour progression in patients diagnosed with early metastatic disease (stages IIIa-c/IV M1a-b) to detect relapse following surgical or adjuvant treatment.
黑色素瘤患者的总体5年生存率为91%。然而，如果发生远处转移（IV期），治愈率则低于15%。因此，在早期阶段（I - III期）检测黑色素瘤可最大程度提高患者的生存几率。我们检测了17种微小RNA（miRNA）组成的一组（MELmiR - 17）在黑色素瘤组织（III期；n = 76例和IV期；n = 10例）以及血清样本（从无黑色素瘤的对照组收集，n = 130例；以及黑色素瘤患者（I/II期，n = 86例；III期，n = 50例；IV期，n = 119例））中的表达情况，这些样本取自澳大利亚和德国的生物样本库。在黑色素瘤组织中，发现“MELmiR - 17”组的成员可作为分期、复发和生存的预测指标。此外，在一项微创血液检测中，当≥4种miRNA表达时，一个由7种miRNA组成的小组（MELmiR - 7）检测黑色素瘤（相对于对照组）的灵敏度较高（93%）且特异性（≥82%）。而且，“MELmiR - 7”小组对黑色素瘤患者总体生存情况的特征描述优于血清乳酸脱氢酶（LDH）和S100B（对数似然比差值 = 11，p < 0.001）。该小组被发现优于目前用于黑色素瘤进展、复发和生存的血清学标志物；并且非常适合监测被诊断为早期转移性疾病（IIIa - c/IV M1a - b期）患者的肿瘤进展情况，以检测手术或辅助治疗后的复发情况。
Zotero 插件
